Ask AI
ProCE Banner Activity

FAQs: Individualizing CDK4/6 Inhibitor–Based Therapy in Breast Cancer

Clinical Thought

This expert FAQ provides key clinical considerations for individualizing CDK4/6 inhibitor–based therapy in patients with HR-positive/HER2-negative breast cancer, with a focus on how efficacy data, treatment duration, toxicity profiles, monitoring requirements, and patient preferences inform treatment selection, adherence, and quality of life. Faculty discuss how RIGHT Choice has influenced the interpretation of aggressive disease vs visceral crisis, the evolving role of everolimus-based combinations after progression on a CDK4/6 inhibitor plus endocrine therapy, and practical strategies for managing fatigue, diarrhea, laboratory changes, and thromboembolic risk in both the adjuvant and advanced disease settings.

Released: July 17, 2026

Share

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Decera Clinical Education.

ProCE Banner

Supporters

Supported by educational grants from Lilly and Novartis.

Lilly

Novartis

Partners

Decera Clinical Education

ProCE Banner

Target Audience

This program is intended for oncologists, physician associates (PAs), nurse practitioners (NPs), nurses, pharmacists, and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate current CDK4/6 inhibitor therapies into treatment plans of appropriate patients with HR+/HER2- early breast cancer in alignment with NCCN Guidelines and expert-recommended best practices

  • Align current CDK4/6 inhibitor treatment in patients with HR+/HER2- metastatic breast cancer with NCCN Guidelines and expert-recommended best practices

  • Manage adverse events associated with CDK4/6 inhibitors to foster and optimize treatment adherence, persistence, and enhance overall outcomes of patients with breast cancer

Financial Disclosures

Primary Author

William J. Gradishar, MD, FACP, FASCO: consultant/advisor/speaker: AstraZeneca, Lilly, Merck, Stemline.

Heather McArthur, MD, MPH, FASCO: consultant/advisor/speaker: ALX, AstraZeneca, Boston Scientific, Daiichi Sankyo, Delcath Systems, Genentech/Roche, Gilead, Lilly, Novartis, Pfizer.

Joanne Mortimer, MD, FACP, FASCO: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, GE Healthcare.